Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Robert Michael Wenham, Sharad A. Ghamande, Ana Oaknin, Jonathan S. Berek, Jose Alejandro Perez-Fidalgo, Pau Guillén Sentís, Daniela Elena Matei, Kan Yonemori, Mayu Yunokawa, Tingting Song, Natalyn Nicole Hawk, Rachael Scott
+1 more Vicky Makker
DOI: 10.1016/j.ijgc.2025.104404
Cited by: 0

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
104404–104404
Publication date
1 February 2026
Language
EN